Iacta Pharmaceuticals and Tallc will enter into a strategic collaboration and licensing agreement to implement Tallc’s SmartCelle technology in clinical development, according to a press release from the companies.
Through the agreement, Iacta gains the use of Tallc’s proprietary SmartCelle micellar technology, a platform for panocular drug delivery. Iacta intends to use the technology to deliver at lease one new ophthalmic therapeutic, according to the release.
“Iacta was formed with the mission of developing and commercializing innovative ocular therapies through novel